Black Friday saleUp to 70% OFF

Diabetes

MCD is topped out the long fast food trend may be SHORTMCD lives on people liking what they eat and eating a lot of it. The Happy Meal is famous. into the business model comes the new wave biologics for obesity and diabetes. the shots that cut down the weight and the food addiction. Insurance companies are jumping on the bandwagon. 1/3 of the people eat half the food. Increasingly, those people are seeking treatment. The fastfood executives know this. Same for the sugar beverages. Anyway, enough said. MC on the monthly chart is stuck at a double top even more obvious on a weekly or daily chart. At present it is stuck in a symmetrical triangle compressing price. The mathematical predictive algorithm forecasts price will move down the remainder of this year. I respect the mathematics and understand the medical trend. LLY makes money supplying insulin and now it makes money actually reversing diabetes and obesity. One way or another it makes money and MCD is supplying the patient flow. In the meanwhile if those patients are detoxified and lower their caloric intake, MCD is the one that suffers a regression of the growth story. I am short MCD and add to my position whenever there is a little upward price movement. Yeah, comarketing donuts with Krispy is an act of desperation.
NYSE:MCDShort
by AwesomeAvani
CMG to split price SHORTCMG has announced a split. Makes sense to make shares more affordable but fractionals are widely available. CMG may be fundamentally challenged by the underpinnings of the fast food markets. that is overeating and rising prices. In the meanwhile the anti-obesity and anti- diabetes trends are pushing hard led by the bological injectable meds from LLY, NVO and others. One third of the people eat one half of the food and now an effective treatment for that addiction is becoming increasingly available. The writing is on the wall and food biz executives can read that writing. Enough said. I am going short on CMG. It's best days of growth may behind it. The company announced plans for 4000 more stores nationwide. Really? Time will tell. I vote with my wallet. My position will not be small. The predictive algo has its forecast. My education included both medicine and engineering. I understand the power of biology and mathematics. I deeply respect both.
NYSE:CMGShort
by AwesomeAvani
PODDDoes look bullish. OverSold on daily, Golden pocket, KDJ Bullish. If we go past my target or hold that level and not go down, it's full continuation of Bull for this stock. Insulet (NASDAQ: PODD) stands as an innovative medical device company committed to enhancing the lives of individuals grappling with diabetes and related conditions through its groundbreaking Omnipod delivery system. PODD mission is deeply rooted in personal experiences, with many of us directly impacted by diabetes. They advocate for their customers, affectionately known as Podders, and the broader diabetes community.
NASDAQ:PODDLong
by Achilly
Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:SANShort
by legacyFXofficial
Two healthcare leaders, which one is best to own? NASDAQ:PODD & NASDAQ:DXCM are leading the sectors recovery. Both are in the Medical Products Industry for diabetes. Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms. For the recent correction, PODD has a -45% deep base while DXCM has a -58%. PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since. So, it really depends on your strategy. If you are looking for aplha then NASDAQ:DXCM is the stock for you but, if you prefer low beta then NASDAQ:PODD is better. Remember that aplha plays in both ways! Which are you trading? I'll trade the first that makes a new high.
NASDAQ:PODDLong
by dpuleo19
Piggyback the profiteers After some conversation with a young single mom and what she goes through to get her and her 2 yr old diabetes meds @ $13hr...f to the big pharma and f to the health care that does not cover such a life saving drug. It's not a conspiracy...it's a cultural failure to recognize how far we have come in such a short time. Some will call it profiteering...sure but it's also about what is done with those profits...what could be done. So I'm in on medtronic with the mission to take their pillaging and raping of the target audience, get some profits and help someone that needs help with their medication. www.diabetes.ca you can donate as well....I just want to take the strain off someone I know personally.
NYSE:MDT
by Honkytime
Tandem Diabetes Care Looks Like a Good Daytrade, SwingTrade PlayStock price has not been fully established yet. Lots of uncertainty, meaning lots of opportunity for short term fluctuations. Stock just underwent reverse split. Currently a "low floater", but with real business operations, not just some cheap pump and dump scam from china or some bitcoin stock. Its a real company with real aspirations of survival. Only problem is they have much better established industry peers like Medtronics. They are still considered a player in their respective industry. Keep on watchlist, watch for movement interday, and if opportunity presents, play it. Reason for watching, low float, recent split, and real company which is a rare thing these days in the stock market it seems like, especially if it has a low float and a real product. No MACD here people, lol. With these risky ones, flat line is a good thing after a big sell off after a reverse split, especially in a bull market. once the sellers are clearly out of the way, that's all you need to know when the stock has a low float, recent reverse split, and healthy trading volume
NASDAQ:TNDMLong
by alipipefitter
2
Greatness Takes Time.I'm seeing some bashing of this company on a few other outlets. I think one thing new investors into VDRM need to realize is that greatness takes time. If you bought into it at 0.06-0.07 because somebody told you it was going to run to a $1 overnight, that's all on the trader and not on the stock. If you look at the chart, this is a very healthy company with a very healthy chart. Slow and steady is the way to go. This company is in store for greatness, and I do believe we see $1 in 2017/2018 however new traders need to realize that a jump from pennies to a dollar happens very rarely unless the company undergoes a R/S or has some suspicious activity going on with it. If you are newly invested into VDRM and are currently sitting at a loss or near a loss I encourage you to hold tight and be patient. if you sell without the intent to buy back in, I suggest you ignore this ticker for the next year or so. We will do great things, we have done great things, and great things will continue to happen slowly but surely with this stock. Millionaires will be made.
OTC:VDRMLong
by Cryptocol